Prostate cancer (PCa) is initially driven by excessive androgen receptor (AR) signaling with
androgen deprivation therapy (ADT) being a major therapeutic approach to its treatment …

Prostate cancer (PC) is one of the leading causes of cancer‑related death in the male
population worldwide. Mortality of PC is dependent on tumor recurrence and its progression …

Metastatic prostate cancer is presently incurable. The oncogenic protein PTOV1, first
described in prostate cancer, was reported as overexpressed and significantly correlated …

Docetaxel treatment is a standard chemotherapy strategy for castration‑resistant prostate
cancer (CRPC), and patients with CRPC eventually develop resistance to treatment …

BACKGROUND Treatment of prostate cancer (PCa) may be improved by identifying
biological mechanisms of tumor growth that directly impact clinical disease progression. We …

The main challenges in developing effective anti-cancer therapies stem from the highly
complex and heterogeneous nature of cancer, including the presence of multiple genetically …

Background: Increasing studies were performed to explore the prognostic value of E-
cadherin in prostatic carcinoma, however, with inconsistent results. Hence, this systematic …

Pemetrexed (MTA) is a folate antimetabolite used for treating non-small cell lung cancer. To
elucidate the mechanisms of pemetrexed resistance in lung cancer, we established …

Background. Drug resistance poses a crucial problem in the treatment of prostate cancer.
Recent studies have shown that chemotherapy agents may cause cancer cells to acquire …

Prostate cancer is a prevalent cancer in men, often treated with chemotherapy. However, it
tumor cells are clinically grows slowly and is heterogeneous, leading to treatment resistance …